Edition:
United Kingdom

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

244.20USD
9:00pm BST
Change (% chg)

$4.63 (+1.93%)
Prev Close
$239.57
Open
$241.31
Day's High
$246.29
Day's Low
$239.00
Volume
109,163
Avg. Vol
104,138
52-wk High
$255.18
52-wk Low
$123.22

Latest Key Developments (Source: Significant Developments)

Ligand Receives $47 Million From WuXi Biologics For Expansion Of Worldwide OmniAb Platform License Agreement
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND RECEIVES $47 MILLION FROM WUXI BIOLOGICS FOR EXPANSION OF WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT.LIGAND PHARMACEUTICALS INC - UPDATES 2018 FULL YEAR AND Q2 FINANCIAL GUIDANCE.LIGAND PHARMACEUTICALS INC - NOW EXPECTS 2018 REVENUE TO BE APPROXIMATELY $226 MILLION.LIGAND PHARMACEUTICALS INC - SEES 2018 ADJUSTED EARNINGS PER DILUTED SHARE APPROXIMATELY $6.15.LIGAND PHARMACEUTICALS INC - ANTICIPATES TOTAL REVENUE FOR Q2 OF 2018 TO BE APPROXIMATELY $82 MILLION TO $84 MILLION.LIGAND PHARMACEUTICALS INC - SEES Q2 ADJUSTED EARNINGS PER DILUTED SHARE TO BE $2.32 TO $2.37.  Full Article

Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics
Thursday, 10 May 2018 

May 10 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING.LIGAND PHARMACEUTICALS INC - KSQ TO BE ABLE TO USE CO'S FULL OMNIAB PLATFORM TO DISCOVER ANTIBODIES.LIGAND - RECEIVED UPFRONT PAYMENT, ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT & REGULATORY MILESTONE PAYMENTS AMONG OTHERS.LIGAND PHARMACEUTICALS INC - KSQ TO BE RESPONSIBLE FOR ALL COSTS RELATED TO ITS ANTIBODY DEVELOPMENT PROGRAM.  Full Article

Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin
Thursday, 22 Mar 2018 

March 22 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​.LIGAND - PURSUANT TO AMENDMENT, RETROPHIN PAID CO $4.6 MILLION, WHICH COVERED AMOUNT DUE UPON INITIATION OF FIRST PHASE 3 TRIAL FOR SPARSENTAN​.LIGAND -CO TO PAY $3 MILLION OF AMOUNT PAID BY RETROPHIN TO BRISTOL-MYERS SQUIBB PURSUANT TO AGREEMENT DATED MAY 27 2006 BETWEEN CO, BRISTOL-MYERS SQUIBB​.  Full Article

Ligand Posts Q4 Adjusted Earnings Per Share $1.31
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $1.31.Q4 GAAP LOSS PER SHARE $0.33.SEES FY 2018 REVENUE ABOUT $164 MILLION.Q4 REVENUE $50.5 MILLION.‍AS OF DECEMBER 31, 2017, LIGAND HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $201.7 MILLION​.‍ESTIMATES THAT CASH EXPENSES FOR 2018 WILL BE IN RANGE OF $34 MILLION TO $35 MILLION​.WITH REVENUE OF $164 MILLION, ADJUSTED EARNINGS PER DILUTED SHARE WOULD BE ABOUT $4.22 FOR 2018​.  Full Article

Ligand Pharma And Glenmark Pharma Enter Into License Agreement
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS.LIGAND PHARMACEUTICALS - ‍ UNDER LICENSE, GLENMARK WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND MULTISPECIFIC ANTIBODIES​.LIGAND PHARMACEUTICALS INC - ‍GLENMARK WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​.LIGAND - ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, REGULATORY MILESTONE PAYMENTS, AMONG OTHERS, FOR PRODUCTS INCORPORATING OMNIAB ANTIBODY​.  Full Article

Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Ligand Pharmaceuticals Inc :Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​.Ligand Pharmaceuticals Inc - ‍currently believes potential royalty revenue growth for 2018 could be in range of 15% to 25% over that of full year 2017​.Ligand Pharmaceuticals Inc - ‍full-year 2018 corporate gross margin is expected to be in range of 94% to 96%​.  Full Article

Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Ligand Pharmaceuticals Inc :Ligand Pharmaceuticals Inc - ‍on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc​.Ligand Pharmaceuticals Inc - ‍Ligand could receive commercial revenue from shipment of Captisol to Meridian for clinical and commercial activities​.Ligand Pharmaceuticals - ‍co granting Meridian exclusive right to use Captisol in Meridian's development and commercialization of a Captisol.Ligand Pharmaceuticals says ‍could potentially receive payments associated with certain licenses, royalties and milestone payments -SEC filing​.  Full Article

Ligand Q3 adjusted earnings per share $0.69
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Ligand Pharmaceuticals Inc ::Ligand reports third quarter 2017 financial results.Q3 adjusted earnings per share $0.69.Q3 earnings per share $0.36.Q3 earnings per share view $0.61 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $134 million to $136 million.Ligand Pharmaceuticals Inc - ‍total revenues for Q3 of 2017 were $33.4 million, compared with $21.6 million for same period in 2016​.Ligand Pharmaceuticals Inc - ‍ligand updates guidance for 2017 revenue to be between $134 and $136 million​.Ligand Pharmaceuticals Inc - ‍adjusted earnings per diluted share is now expected to be between $2.95 and $3.00 for 2017 ​.Q3 revenue view $30.9 million -- Thomson Reuters I/B/E/S.FY 2017 earnings per share view $2.95, revenue view $134.5 million -- Thomson Reuters I/B/E/S.  Full Article

Ligand to acquire Crystal Bioscience
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Ligand Pharmaceuticals Inc :Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments.Ligand Pharmaceuticals Inc - ‍transaction expected to be accretive to revenue and earnings beginning in 2018​.Ligand Pharmaceuticals Inc - Ligand will pay Crystal shareholders $25 million in cash at closing, up to an additional $10.5 million of success-based milestones.Ligand Pharmaceuticals Inc says ‍including acquisition, Ligand now expects 2017 total revenues to be at least $134 million​.Ligand Pharmaceuticals Inc says estimates with revenue of $134 million, FY 2017 adjusted earnings per share would be approximately $2.93​.Ligand Pharmaceuticals Inc expects 2017 earnings per share would be approximately $2.93.  Full Article

Ligand Pharmaceuticals Q2 earnings per share $0.26
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Ligand Pharmaceuticals Inc :Ligand reports second quarter 2017 financial results.Q2 adjusted earnings per share $0.67.Q2 earnings per share $0.26.Q2 earnings per share view $0.46 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue at least $133 million.  Full Article